Jun 16, 2020 | Controlled Release, Drug Bioavailability, Main Blog, Peptide |
Improving the solubility of poorly soluble APIs remains one of the biggest challenges for pharmaceutical companies. Not to mention the lengthy and costly drug approval processes, generic incursion, rising development costs and the need for novel adherence strategies,...
